Adaptive radiation plus pembrolizumab for stage IV lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a personalized (“adaptive”) radiation plan combined with pembrolizumab, and possibly chemotherapy, for advanced stage IV lung cancer. It aims to improve cancer control while carefully managing side effects, including in patients with certain brain metastases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign informed consent.
- Your lung cancer is non-small cell stage IVA/IVB (including M1b or M1c) or locally advanced and not eligible for standard chemoradiation.
- You have measurable cancer on scans (evaluable disease) and your tumor can be checked for PD-L1 (programmed death-ligand 1) from a tissue sample done within 6 months.
- You have an active general condition good enough for treatment (ECOG 0–2) and your kidneys/liver and other organs are functioning well enough for the planned drugs.
- You can have immunotherapy as decided by your study doctor, and—if you can become pregnant—you use highly effective birth control and have a recent negative pregnancy test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether low-dose IL-2 combined with pembrolizumab can help treat stage IV non-small cell lung cancer that has not had prior advanced treatment. It may be an option if your tumor has certain immune-marker findings (PD-L1) and you meet safety requirements.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This Phase 1/2 study tests pembrolizumab (an immune-based cancer treatment) either alone or with chemotherapy in people newly diagnosed with stage IV non-small cell lung cancer (NSCLC). It looks at how well the treatments work and whether they are safe, especially in people who haven’t had treatment yet for metastatic disease.
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
This study tests a drug called pembrolizumab (an immunotherapy that helps your immune system fight cancer) combined with two chemotherapy drugs, without radiation. It is for people with stage III lung cancer that has not spread and has a high PD-L1 level. The goal is to see if this treatment can shrink or control the cancer better than the usual approach.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Hear when a new Stage IV Lung Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.